<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9805">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01749605</url>
  </required_header>
  <id_info>
    <org_study_id>201005757</org_study_id>
    <nct_id>NCT01749605</nct_id>
  </id_info>
  <brief_title>A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <authority>United States: University of Iowa Institutional Review Boards</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study to compare the efficacy and safety of 3-day, twice-daily regimens of
      nitrofurantoin and ciprofloxacin in emergency department (ED) patients presenting with UBC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>clinical cure at 7 days</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>7-day questionnaires included a table to measure the severity of the symptoms and their impact on daily life. Using this table, the investigators calculated a severity score (left hand column) and a bothersome score (right hand column), with a maximum score of 21</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Uncomplicated Bacterial Cystitis</condition>
  <arm_group>
    <arm_group_label>nitrofurantoin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin 250 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days</intervention_name>
    <arm_group_label>nitrofurantoin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciprofloxacin 250 mg BID x 3 days</intervention_name>
    <arm_group_label>Ciprofloxacin 250 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pre-menopausal females

          -  ages 18-45 years old

          -  symptoms of a UTI (dysuria, frequency, urgency)

        Exclusion Criteria:

          -  Onset of symptoms &gt;7 days prior to the ED visit

          -  Non-English speaking

          -  Symptoms of pyelonephritis

          -  Diabetic

          -  Indications of sepsis

          -  Immunocompromised

          -  Currently using prophylactic antimicrobials

          -  Medications that could interfere with study drug

          -  Pregnant

          -  Lactating

          -  History of kidney or liver disease

          -  Vaginal symptoms

          -  Presence of a urinary catheter

          -  Treatment for UBC &lt;2 weeks prior to ED visit

          -  Known allergy to study drug

          -  Unavailable for follow-up
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 12, 2012</lastchanged_date>
  <firstreceived_date>December 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Brett A Faine</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Nitrofurantoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
